Farhaan S Vahidy1, Mohammad H Rahbar2, Hongjian Zhu2, Paul J Rowan2, Arvind B Bambhroliya2, Sean I Savitz2. 1. From the Department of Neurology, McGovern Medical School (F.S.V., A.B.B., S.I.S.), Department of Epidemiology, Human Genetics and Environmental Sciences (M.H.R.), Department of Biostatistics (H.Z.), and Department of Management, Policy and Community Health (P.J.R.), School of Public Health, University of Texas Health at Houston. Farhaan.Vahidy@uth.tmc.edu. 2. From the Department of Neurology, McGovern Medical School (F.S.V., A.B.B., S.I.S.), Department of Epidemiology, Human Genetics and Environmental Sciences (M.H.R.), Department of Biostatistics (H.Z.), and Department of Management, Policy and Community Health (P.J.R.), School of Public Health, University of Texas Health at Houston.
Abstract
BACKGROUND AND PURPOSE: Bone marrow-derived mononuclear cells (BMMNCs) offer the promise of augmenting poststroke recovery. There is mounting evidence of safety and efficacy of BMMNCs from preclinical studies of ischemic stroke; however, their pooled effects have not been described. METHODS: Using Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines, we conducted a systematic review of preclinical literature for intravenous use of BMMNCs followed by meta-analyses of histological and behavioral outcomes. Studies were selected based on predefined criteria. Data were abstracted by 2 independent investigators. After quality assessment, the pooled effects were generated using mixed-effect models. Impact of possible biases on estimated effect size was evaluated. RESULTS: Standardized mean difference and 95% confidence interval for reduction in lesion volume was significantly beneficial for BMMNC treatment (standardized mean difference: -3.3; 95% confidence interval, -4.3 to -2.3). n=113 each for BMMNC and controls. BMMNC-treated animals (n=161) also had improved function measured by cylinder test (standardized mean difference: -2.4; 95% confidence interval, -3.1 to -1.6), as compared with controls (n=205). A trend for benefit was observed for adhesive removal test and neurological deficit score. Study quality score (median: 6; Q1-Q3: 5-7) was correlated with year of publication. There was funnel plot asymmetry; however, the pooled effects were robust to the correction of this bias and remained significant in favor of BMMNC treatment. CONCLUSIONS: BMMNCs demonstrate beneficial effects across histological and behavioral outcomes in animal ischemic stroke models. Although study quality has improved over time, considerable degree of heterogeneity calls for standardization in the conduct and reporting of experimentation.
BACKGROUND AND PURPOSE: Bone marrow-derived mononuclear cells (BMMNCs) offer the promise of augmenting poststroke recovery. There is mounting evidence of safety and efficacy of BMMNCs from preclinical studies of ischemic stroke; however, their pooled effects have not been described. METHODS: Using Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines, we conducted a systematic review of preclinical literature for intravenous use of BMMNCs followed by meta-analyses of histological and behavioral outcomes. Studies were selected based on predefined criteria. Data were abstracted by 2 independent investigators. After quality assessment, the pooled effects were generated using mixed-effect models. Impact of possible biases on estimated effect size was evaluated. RESULTS: Standardized mean difference and 95% confidence interval for reduction in lesion volume was significantly beneficial for BMMNC treatment (standardized mean difference: -3.3; 95% confidence interval, -4.3 to -2.3). n=113 each for BMMNC and controls. BMMNC-treated animals (n=161) also had improved function measured by cylinder test (standardized mean difference: -2.4; 95% confidence interval, -3.1 to -1.6), as compared with controls (n=205). A trend for benefit was observed for adhesive removal test and neurological deficit score. Study quality score (median: 6; Q1-Q3: 5-7) was correlated with year of publication. There was funnel plot asymmetry; however, the pooled effects were robust to the correction of this bias and remained significant in favor of BMMNC treatment. CONCLUSIONS: BMMNCs demonstrate beneficial effects across histological and behavioral outcomes in animal ischemic stroke models. Although study quality has improved over time, considerable degree of heterogeneity calls for standardization in the conduct and reporting of experimentation.
Authors: Jennifer S Lees; Emily S Sena; Kieren J Egan; Ana Antonic; Simon A Koblar; David W Howells; Malcolm R Macleod Journal: Int J Stroke Date: 2012-06-12 Impact factor: 5.266
Authors: Katherine S Button; John P A Ioannidis; Claire Mokrysz; Brian A Nosek; Jonathan Flint; Emma S J Robinson; Marcus R Munafò Journal: Nat Rev Neurosci Date: 2013-04-10 Impact factor: 34.870
Authors: Sean I Savitz; Vivek Misra; Mallik Kasam; Harrinder Juneja; Charles S Cox; Susan Alderman; Imo Aisiku; Siddhartha Kar; Adrian Gee; James C Grotta Journal: Ann Neurol Date: 2011-07 Impact factor: 10.422
Authors: Paulo Henrique Rosado-de-Castro; Felipe da Rocha Schmidt; Valeria Battistella; Sergio Augusto Lopes de Souza; Bianca Gutfilen; Regina Coeli dos Santos Goldenberg; Tais Hanae Kasai-Brunswick; Leandro Vairo; Rafaella Monteiro Silva; Eduardo Wajnberg; Pedro Emmanuel Alvarenga Americano do Brasil; Emerson Leandro Gasparetto; Angelo Maiolino; Soniza Vieira Alves-Leon; Charles Andre; Rosalia Mendez-Otero; Gabriel Rodriguez de Freitas; Lea Mirian Barbosa da Fonseca Journal: Regen Med Date: 2013-03 Impact factor: 3.806
Authors: Marcelo M Cardoso; Edna C S Franco; Celice C de Souza; Michelle C da Silva; Amauri Gouveia; Walace Gomes-Leal Journal: Inflammation Date: 2013-02 Impact factor: 4.092
Authors: Charles S Cox; Robert A Hetz; George P Liao; Benjamin M Aertker; Linda Ewing-Cobbs; Jenifer Juranek; Sean I Savitz; Margaret L Jackson; Anna M Romanowska-Pawliczek; Fabio Triolo; Pramod K Dash; Claudia Pedroza; Dean A Lee; Laura Worth; Imoigele P Aisiku; Huimahn A Choi; John B Holcomb; Ryan S Kitagawa Journal: Stem Cells Date: 2016-11-23 Impact factor: 6.277